Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Cool racing game, online racing games bike racing.
Popular Articles

World Hepatitis Day - Tackling "Inadequate" Testing: Dried Blood Spot And Oral Fluids Offer Chance To Extend Hepatitis Screening
On World Hepatitis Day, Concateno, a provider of drug testing and medical screening solutions, calls for the increased use of a broader range of Hepatitis testing techniques including dried blood spot and oral fluid testing. The company argues that these cost-effective and easy to use methods are often more convenient than collecting whole blood samples, and could significantly increase screening among injecting drug users (IDUs), one of the highest risk groups for infection.
generic viagra online
Advocates At Kenya Conference Explore New Strategies To Combat HIV/AIDS In Africa
Nearly 30 years after the emergence of HIV/AIDS, the global health community must develop new strategies to curb the spread of the disease in sub-Saharan Africa, some experts said Tuesday ahead of the Global Citizens Summit for Social Mobilization to End AIDS in Nairobi, Kenya, AFP/Google.com reports. The advocates also stressed the need for innovative approaches to health financing as international donors shift their attention toward other issues and as the ongoing economic downturn threatens fundraising prospects. The conference, which opens Wednesday, includes participants from 32 countries, primarily in Africa.According to Wasai Jacob Nanjakululu of Oxfam, about 90% of HIV-positive people are unaware of their status and 70% of people in need of treatment are not accessing medical care. Leonard Okello, an HIV/AIDS specialist with ActionAid International, added that the global health community is "far from winning the struggle against" HIV/AIDS. Okello said the conference will examine the shortcomings of earlier HIV/AIDS policies and explore new methods to address the disease. "There are a lot of res in HIV/AIDS programs but not much of that reaches the community," Okello said, asking, "What is it that we should radically change?" (AFP/Google.com, 5/26). According to IRIN/PlusNews, conference participants also plan to discuss "people-centered" approaches to combating HIV/AIDS at the Nairobi meeting. ActionAid Report Calls For Improvements in Basic Health Care To Address HIV/AIDS
News of the day
Nanoparticles In Environment Estimated By Novel Approach
Without knowing how much of an industrial chemical is being produced, it is almost impossible for scientists to determine if it poses any threat to the environment or human health.
Diagnostics

Endeavor Drug-Eluting Stent Is First To Receive CE Mark For Treating Acute Coronary Syndrome

Medtronic, Inc. (NYSE: MDT), announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE (Conformité Européene) Mark approval for treating patients with acute coronary syndrome (ACS), which includes unstable angina and acute myocardial infarction (AMI), commonly known as heart attack. Medtronic is launching the unique ACS indication for the Endeavor DES today at PCR, a large and prestigious international meeting of interventional cardiologists. At this meeting today, Prof. Martin Rothman of the London Chest Hospital in the U.K. released positive new 12Ò€òmonth data from the international realÒ€òworld registry EÒ€òFive study (n=8,314) that show comparable outcomes for Endeavor DES patients with and without ACS . "Considering the distinctive safety record of the Endeavor stent, this indication for ACS makes perfect sense," said Prof. Rothman. "Results from the EÒ€òFive study support the use of the Endeavor stent in realÒ€òworld clinical practice, including ACS patients." Clinical research shows that ACS patients are at higher risk of stent thrombosis and mortality than nonÒ€òACS patients. ACS is a complex disease state for which drugÒ€òeluting stents are sometimes avoided due to concerns over longÒ€òterm safety and patient compliance with antiplatelet medication. "Of critical importance for safety, the biocompatibility of the Endeavor stent allows rapid and complete healing of the vessel wall," explained Sean Salmon, vice president and general manager of Medtronic CardioVascular"s Coronary and Peripheral business. "We believe that this healthy healing is the key to longÒ€òterm safety and efficacy." The EÒ€òFive study demonstrated no statistically significant difference on the primary endpoint - the rate of major adverse cardiac events (MACE) at one year - between ACS patients (7.8 percent, n=3,973) and nonÒ€òACS patients (7.2 percent, n=4,341). Rates of death, MI and late stent thrombosis (LST) at one year were similarly low and comparable between the two groups. - AllÒ€òcause mortality - 2.7% ACS, 2.2%, nonÒ€òACS - Cardiac death - 2.0% ACS, 1.5% nonÒ€òACS - MI - 1.8% ACS, 1.5% nonÒ€òACS - Cardiac death + MI - 3.4% ACS, 2.7% nonÒ€òACS - LST (ARC def/prob) - 0.5% ACS, 0.3% nonÒ€òACS Low and similar rates of standard efficacy measures were also observed, including target lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel failure (TVF). On all these measures, there were no statistically significant differences between the ACS and nonÒ€òACS groups. Medtronic"s Endeavor stent originally received the CE mark in August 2005 as a treatment for coronary artery disease. This latest approval enables Medtronic to market the Endeavor DES specifically for ACS patients in the European Union, and all other countries that recognize the CE Mark. These countries do not include the United States or Japan, where the Endeavor DES is also commercially available but is not indicated for ACS patients. Medtronic, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009